Rocket Pharmaceuticals Inc to Acquire Renovacor, Extending Leadership in AAV-Based Cardiac Gene Therapy Call Transcript
Good day, and thank you for standing by. Welcome to the Rocket Pharmaceuticals Business Update Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Jessie Yeung, Vice President of IR and Corporate Finance. Please go ahead.
Thank you, operator, and good morning, everyone. Thanks for joining our call today to discuss the combination of Rocket Pharma and Renovacor. This is Jessie Yeung, Vice President of Investor Relations and Corporate Finance, at Rocket Pharmaceuticals. With me on the line today is Dr. Gaurav Shah, CEO of Rocket Pharmaceuticals; and Martin Wilson, Rocket's General Counsel and Chief Compliance Officer.
Before we begin, I would like to briefly discuss the use of forward-looking statements on this conference call. Statements we make on this call may include forward-looking statements, and these forward-looking statements are subject to loan and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |